Skip to main content

Table 2 Antifungal susceptibility of 149 isolates and categorical agreement between CLSI 2008 and 2012

From: Impact of inappropriate antifungal therapy according to current susceptibility breakpoints on Candida bloodstream infection mortality, a retrospective analysis

Species/ antifungal (n)

MIC range

(mg/L)

MIC 50

(mg/L)

MIC 90

(mg/L)

CLSI 2008

n (%)

CLSI 2012

n (%)

S

I

R

S

SDDa/I

R

C. albicans (60)

 Fluconazole

≤ 1–8

1

1

60 (100)

56 (93.3)

2 (3.3)

2 (3.3)

 Voriconazole

≤ 0.12

0.12

0.12

60 (100)

60 (100)

 Caspofungin

≤ 0.25–1

0.25

0.25

60 (100)

56 (93.3)

1 (1.6)

3 (5)

 Micafungin

≤ 0.06–1

0.06

0.06

60 (100)

58 (96.6)

1 (1.6)

1 (1.6)

C. tropicalis (34)

 Fluconazole

≤ 1–8

1

1

34 (100)

32 (94.1)

1 (2.9)

1 (2.9)

 Voriconazole

≤ 0.12

0.12

0.12

34 (100)

34 (100)

 Caspofungin

≤ 0.25–1

0.25

0.25

34 (100)

34 (100)

 Micafungin

≤ 0.06–0.5

0.06

0.06

34 (100)

34 (100)

C. glabrata (30)

 Fluconazole

≤ 1–64

4

8

28 (93.3)

2 (6.6)

0

28 (93.3)

2 (6.6)

 Caspofungin

< 0.25–1

0.25

0.25

30 (100)

29 (96.6)

1 (3.3)

 Micafungin

< 0.06–0.5

0.06

0.06

30 (100)

29 (96.6)

1 (3.3)

C. parapsilosis (15)

 Fluconazole

≤ 1–8

1

8

15 (100)

13 (86.6)

1 (6.6)

1 (6.6)

 Voriconazole

≤ 0.12–0.25

0.12

0.12

15 (100)

15 (100)

 Caspofungin

< 0.25–1

1

1

15 (100)

  

15 (100)

 Micafungin

< 0.06–1

0.5

1

15 (100)

  

15 (100)

C. guilliermondi (3)

 Fluconazole

2–8

2

8

3 (100)

  

 Voriconazole

< 0.12

< 0.12

< 0.12

3 (100)

  

 Caspofungin

0.25–1

0.25

1

3 (100)

  

 Micafungin

0.5

0.5

0.5

3 (100)

  

C. kruzei (2)

 Voriconazole

≤ 0.12

0.12

0.12

2 (100)

  

2 (100)

 Caspofungin

≤ 0.25–0.5

0.25

0.5

2 (100)

  

1

1

 Micafungin

0.12

0.12

0.12

2 (100)

  

2

Otherb (5)

 Fluconazole

≤ 1–16

2

16

3 (60)

2 (40)

 

 Voriconazole

≤ 0.12

0.12

0.12

5 (100)

 Caspofungin

≤ 0.25- > 4

0.25

4

4 (80)

 Micafungin

< 0.06- > 4

0.12

4

4 (80)

  1. MIC minimal inhibitory concentration, S susceptible, I intermediate, R resistant, SDD susceptible dose dependent, CLSI Clinical Laboratory Standards Institute
  2. aSDD applies for fluconazole and voriconazole instead of intermediate
  3. bOther species: C. lusitaniae, C. pelliculosa, C. norvegensis, C. lypolitica, C. inconspicua